{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(3)"],"submitter":["Derer S"],"pubmed_abstract":["Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab) therapy. However, the mechanisms by which constitutively activated KRAS (KRAS(G12V)) impairs effector mechanisms of EGFR-Abs are incompletely understood. Here, we established isogenic cell line models to systematically investigate the impact of KRAS(G12V) on tumor growth in mouse A431 xenograft models as well as on various modes of action triggered by EGFR-Abs in vitro. KRAS(G12V) impaired EGFR-Ab-mediated growth inhibition by stimulating receptor-independent downstream signaling. KRAS(G12V) also rendered tumor cells less responsive to Fc-mediated effector mechanisms of EGFR-Abs-such as complement-dependent cytotoxicity (CDC) and Ab-dep"],"journal":["Neoplasia (New York, N.Y.)"],"pagination":["190-205"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3323897"],"repository":["biostudies-literature"],"pubmed_title":["Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression."],"pmcid":["PMC3323897"],"pubmed_authors":["Klausz K","Dechant M","Derer S","Schneider-Merck T","Nagelmeier I","Parren PW","Kellner C","Peipp M","Overdijk MB","Schlaeth M","Scheel AH","Lohse S","Valerius T","van de Winkel JG","Lammerts van Bueren JJ","Berger S"],"additional_accession":[]},"is_claimable":false,"name":"Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.","description":"Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab) therapy. However, the mechanisms by which constitutively activated KRAS (KRAS(G12V)) impairs effector mechanisms of EGFR-Abs are incompletely understood. Here, we established isogenic cell line models to systematically investigate the impact of KRAS(G12V) on tumor growth in mouse A431 xenograft models as well as on various modes of action triggered by EGFR-Abs in vitro. KRAS(G12V) impaired EGFR-Ab-mediated growth inhibition by stimulating receptor-independent downstream signaling. KRAS(G12V) also rendered tumor cells less responsive to Fc-mediated effector mechanisms of EGFR-Abs-such as complement-dependent cytotoxicity (CDC) and Ab-dep","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Mar","modification":"2025-07-06T03:04:42.786Z","creation":"2025-07-06T03:04:42.786Z"},"accession":"S-EPMC3323897","cross_references":{"pubmed":["22496619"],"doi":["10.1593/neo.111636"]}}